文档介绍:肝移植术后乙型肝炎病毒再感染的预防与诊治
文章来源毕业论文网
毕业论文
           作者:夏杰杨占宇陈佳廖睿张南郭鹏周吉军王宇明 
【摘要】&nbsp; 目的探讨肝移植术后HBV再感染的预防与诊治。方法回顾性分析1999年8月至2004年12月98例肝移植患者临床资料。其中40例术后采用拉米夫定(lamivudine,LAM)单用方案预防HBV再感染,58例采用LAM+乙型肝炎免疫球蛋白(HBIg)联用方案。对HBV再感染者予以阿德福韦(adefovir,ADV)抗病毒治疗。结果 17例肝移植患者出现HBV再感染,其中14例明确存在YMDD变异。术前血清HBV DNA阳性者术后2年HBV再感染率显著高于阴性者(P<),前者术后采用LAM+HBIg联合预防者其HBV再感染率显著低于单用LAM预防者(P<),而后者术后LAM单用和LAM+HBIg联用两组之间差异无统计学意义(P>)。15例HBV再感染者改用ADV治疗后,13例(%)于治疗后1~3个月HBV DNA转阴。结论术前降低血清HBV DNA水平和术后LAM+HBIg联合预防方案能有效降低肝移植术后HBV再感染率。对术前HBV DNA阴性者,术后可选用LAM单药预防方案。ADV能够有效地治疗肝移植术后HBV再感染,抑制HBV变异株的复制。
【关键词】&nbsp; 肝移植; 乙型肝炎病毒再感染; 乙型肝炎免疫球蛋白
Prevention and treatment of HBV reinfection after liver transplantation&nbsp;
&nbsp;&nbsp;&nbsp; 【Abstract】&nbsp; Objective&nbsp; To study the prevention and treatment of HBV reinfection after liver transplantation. Methods&nbsp; A retrospective study was carried out on 98 patients who received orthotopic liver transplantation (OLT) from August 1999 to December 2004. Fiftytwo patients were HBV DNApositive and 46 HBV DNAnegative. All patients were divided into 4 groups: Group A [HBV DNApositive patients treated by lamivudine (LAM), n=21], Group B (HBV DNAnegative patients treated by LAM, n=19), Group C [HBV DNApositive patients treated by LAM+ Hepatis B immunoglobulin (HBIG), n=31] and Group D (HBV D